Neos Therapeutics Announces Pricing of Initial Public Offering

DALLAS/FORT WORTH, Texas -- Neos Therapeutics, Inc. ("Neos" or "the Company") today announced the pricing of its initial public offering of 4,800,000 shares of common stock at an initial public offering price of $15.00 per share. In addition, Neos has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock at the initial public offering price. The shares of Neos' common stock are expected to begin trading on the NASDAQ Global Market on July 23, 2015 under the ticker symbol "NEOS." The offering is expected to close on July 28, 2015, subject to customary closing conditions.

UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are acting as joint book-running managers and JMP Securities is acting as a lead manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 22, 2015. The offering will be made only by means of a prospectus, copies of which may be obtained from the offices of UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone: (888) 827-7275; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: [email protected]; or RBC Capital Markets, LLC, Attention: Prospectus Department, 200 Vesey Street, 8th Floor, New York, NY 10281.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient-friendly ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

Vipin Garg, Chief Executive Officer, President and Director
Neos Therapeutics
(919) 434-6643

Richard I. Eisenstadt, Chief Financial Officer
Neos Therapeutics
(972) 408-1389

David Carey, Investor Relations
Lazar Partners
(212) 867-1768

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.